Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure
BackgroundMultidrug-resistant (MDR) bacterial infection causes difficulty in the therapy of peritoneal dialysis-associated peritonitis (PDAP); however, there are few studies on multidrug-resistant organism (MDRO)-PDAP. In view of growing concerns about MDRO-PDAP, the aim of this study was to investi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1132695/full |
| _version_ | 1797830038969647104 |
|---|---|
| author | Shizheng Guo Liming Yang Xueyan Zhu Xiaoxuan Zhang Lingfei Meng Xinyang Li Siyu Cheng Xiaohua Zhuang Shengmao Liu Wenpeng Cui |
| author_facet | Shizheng Guo Liming Yang Xueyan Zhu Xiaoxuan Zhang Lingfei Meng Xinyang Li Siyu Cheng Xiaohua Zhuang Shengmao Liu Wenpeng Cui |
| author_sort | Shizheng Guo |
| collection | DOAJ |
| description | BackgroundMultidrug-resistant (MDR) bacterial infection causes difficulty in the therapy of peritoneal dialysis-associated peritonitis (PDAP); however, there are few studies on multidrug-resistant organism (MDRO)-PDAP. In view of growing concerns about MDRO-PDAP, the aim of this study was to investigate the clinical features, risk factors of treatment failure, and causative pathogens of MDRO-PDAP.MethodsIn total, 318 patients who underwent PD between 2013 and 2019 were included in this multicenter retrospective study. Clinical features, patient outcomes, factors related to treatment failure, and microbiological profiles associated with MDRO-PDAP were analyzed and risk factors for treatment failure associated with MDR-Escherichia coli (E. coli) were further discussed.ResultsOf 1,155 peritonitis episodes, 146 eligible episodes of MDRO-PDAP, which occurred in 87 patients, were screened. There was no significant difference in the composition ratio of MDRO-PDAP between 2013–2016 and 2017–2019 (p > 0.05). E. coli was the most prevalent MDRO-PDAP isolate, with high sensitivity to meropenem (96.0%) and piperacillin/tazobactam (89.1%). Staphylococcus aureus was the second most common isolate and was susceptible to vancomycin (100%) and linezolid (100%). Compared to non-multidrug-resistant organism-PDAP, MDRO-PDAP was associated with a lower cure rate (66.4% vs. 85.5%), higher relapse rate (16.4% vs. 8.0%), and higher treatment failure rate (17.1% vs.6.5%). Dialysis age [odds ratio (OR): 1.034, 95% confidence interval (CI): 1.016–1.052, p < 0.001] and >2 previous peritonitis episodes (OR: 3.400, 95% CI: 1.014–11.400, p = 0.047) were independently associated with treatment failure. Furthermore, longer dialysis age (OR: 1.033, 95% CI: 1.003–1.064, p = 0.031) and lower blood albumin level (OR: 0.834, 95% CI: 0.700–0.993, p = 0.041) increased the risk of therapeutic failure for MDR-E. coli infection.ConclusionThe proportion of MDRO-PDAP has remained high in recent years. MDRO infection is more likely to result in worse outcomes. Dialysis age and previous multiple peritonitis infections were significantly associated with treatment failure. Treatment should be promptly individualized based on local empirical antibiotic and drug sensitivity analyses. |
| first_indexed | 2024-04-09T13:29:42Z |
| format | Article |
| id | doaj.art-7e4e7906ea2147c9a23b20174f172fea |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-09T13:29:42Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-7e4e7906ea2147c9a23b20174f172fea2023-05-10T04:29:08ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-05-011010.3389/fmed.2023.11326951132695Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failureShizheng Guo0Liming Yang1Xueyan Zhu2Xiaoxuan Zhang3Lingfei Meng4Xinyang Li5Siyu Cheng6Xiaohua Zhuang7Shengmao Liu8Wenpeng Cui9Division of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, First Hospital of Jilin University – The Eastern Division, Changchun, ChinaDivision of Nephrology, Jilin Central Hospital, Jilin, ChinaDivision of Nephrology, Jilin FAW General Hospital, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaDivision of Nephrology, The Second Hospital of Jilin University, Changchun, ChinaBackgroundMultidrug-resistant (MDR) bacterial infection causes difficulty in the therapy of peritoneal dialysis-associated peritonitis (PDAP); however, there are few studies on multidrug-resistant organism (MDRO)-PDAP. In view of growing concerns about MDRO-PDAP, the aim of this study was to investigate the clinical features, risk factors of treatment failure, and causative pathogens of MDRO-PDAP.MethodsIn total, 318 patients who underwent PD between 2013 and 2019 were included in this multicenter retrospective study. Clinical features, patient outcomes, factors related to treatment failure, and microbiological profiles associated with MDRO-PDAP were analyzed and risk factors for treatment failure associated with MDR-Escherichia coli (E. coli) were further discussed.ResultsOf 1,155 peritonitis episodes, 146 eligible episodes of MDRO-PDAP, which occurred in 87 patients, were screened. There was no significant difference in the composition ratio of MDRO-PDAP between 2013–2016 and 2017–2019 (p > 0.05). E. coli was the most prevalent MDRO-PDAP isolate, with high sensitivity to meropenem (96.0%) and piperacillin/tazobactam (89.1%). Staphylococcus aureus was the second most common isolate and was susceptible to vancomycin (100%) and linezolid (100%). Compared to non-multidrug-resistant organism-PDAP, MDRO-PDAP was associated with a lower cure rate (66.4% vs. 85.5%), higher relapse rate (16.4% vs. 8.0%), and higher treatment failure rate (17.1% vs.6.5%). Dialysis age [odds ratio (OR): 1.034, 95% confidence interval (CI): 1.016–1.052, p < 0.001] and >2 previous peritonitis episodes (OR: 3.400, 95% CI: 1.014–11.400, p = 0.047) were independently associated with treatment failure. Furthermore, longer dialysis age (OR: 1.033, 95% CI: 1.003–1.064, p = 0.031) and lower blood albumin level (OR: 0.834, 95% CI: 0.700–0.993, p = 0.041) increased the risk of therapeutic failure for MDR-E. coli infection.ConclusionThe proportion of MDRO-PDAP has remained high in recent years. MDRO infection is more likely to result in worse outcomes. Dialysis age and previous multiple peritonitis infections were significantly associated with treatment failure. Treatment should be promptly individualized based on local empirical antibiotic and drug sensitivity analyses.https://www.frontiersin.org/articles/10.3389/fmed.2023.1132695/fullperitoneal dialysisperitonitismulti-drug resistantantimicrobial sensitivity patternrisk factors |
| spellingShingle | Shizheng Guo Liming Yang Xueyan Zhu Xiaoxuan Zhang Lingfei Meng Xinyang Li Siyu Cheng Xiaohua Zhuang Shengmao Liu Wenpeng Cui Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure Frontiers in Medicine peritoneal dialysis peritonitis multi-drug resistant antimicrobial sensitivity pattern risk factors |
| title | Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure |
| title_full | Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure |
| title_fullStr | Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure |
| title_full_unstemmed | Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure |
| title_short | Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure |
| title_sort | multidrug resistant organism peritoneal dialysis associated peritonitis clinical and microbiological features and risk factors of treatment failure |
| topic | peritoneal dialysis peritonitis multi-drug resistant antimicrobial sensitivity pattern risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1132695/full |
| work_keys_str_mv | AT shizhengguo multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT limingyang multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT xueyanzhu multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT xiaoxuanzhang multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT lingfeimeng multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT xinyangli multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT siyucheng multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT xiaohuazhuang multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT shengmaoliu multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure AT wenpengcui multidrugresistantorganismperitonealdialysisassociatedperitonitisclinicalandmicrobiologicalfeaturesandriskfactorsoftreatmentfailure |